DEALS: Affymetrix lands ParAllele acquisition


Affymetrix lands ParAllele acquisition


DEALS

WHO

WITH

WHAT

SCOOP

Affymetrix

ParAllele BioScience

$120M buyout

When used with Affymetrix GeneChip technology, ParAllele's proprietary assay effectively gives researchers a powerful "molecular microscope" for examining the entire genome.

NBTY

Solgar Vitamin and Herb

$115M buyout

Solgar manufactures and distributes nutritional supplements, including multivitamins, minerals, botanicals and specialty formulas.

Qiagen

artus Gesellschaft

$39.2M buyout

Artus is a leader in PCR-based molecular diagnostic tests for pathogenenic, genotyping and pharmacogenomic testing.

Chromos Molecular Systems

Targeted Molecules

Acquisition, stock and notes

Targeted Molecules has been focused on the research and development of two antibody product candidates for the treatment of multiple sclerosis and acute thrombosis.

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.